checkAd
    Startseite > Aktien > Cognition Therapeutics > Nachrichten
    Cognition Therapeutics
    Aktie
    ISIN: US19243B1026 WKN: A3C46P SYM: CGTX Land USA
    Zur Watchlist hinzufügen Zum Portfolio hinzufügen
    2,0700
     
    USD
    +0,0900 USD
    +4,55 %
    Letzter Kurs 02:00:00 Nasdaq
    Geldkurs
    11.06.24
    2,0300
     
    USD
    700 STK
    Briefkurs
    11.06.24
    2,0800
     
    USD
    700 STK

    Cognition Therapeutics Aktie kaufen

    Kauf
    Verkauf
    ISIN: US19243B1026 WKN: A3C46P SYM: CGTX Land USA

    Neueste Nachrichten

    Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease
    21.05.24 · globenewswire · Cognition Therapeutics
    Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
    07.05.24 · globenewswire · Cognition Therapeutics
    Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
    29.04.24 · globenewswire · Cognition Therapeutics
    Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
    22.04.24 · globenewswire · Cognition Therapeutics
    Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference
    02.04.24 · globenewswire · Cognition Therapeutics
    Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024
    01.04.24 · globenewswire · Cognition Therapeutics
    Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
    26.03.24 · globenewswire · Cognition Therapeutics
    Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
    15.03.24 · globenewswire · Cognition Therapeutics
    Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock
    14.03.24 · globenewswire · Cognition Therapeutics
    Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock
    12.03.24 · globenewswire · Cognition Therapeutics
    Cognition Therapeutics Announces Proposed Public Offering of Common Stock
    11.03.24 · globenewswire · Cognition Therapeutics
    Cognition Therapeutics Presents Analyses at AD/PD 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies
    06.03.24 · globenewswire · Cognition Therapeutics